<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04766424</url>
  </required_header>
  <id_info>
    <org_study_id>10055552</org_study_id>
    <secondary_id>1R01NR018891-01A1</secondary_id>
    <nct_id>NCT04766424</nct_id>
  </id_info>
  <brief_title>Sleep Technology Intervention to Target Cardiometabolic Health</brief_title>
  <acronym>STITCH</acronym>
  <official_title>Effects of a Behavioral Sleep Extension Intervention on Cardiometabolic Risk Factors Among Patients With Elevated BP/Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Nursing Research (NINR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to test the efficacy of a behavioral sleep extension intervention&#xD;
      on sleep duration, cardio-metabolic disease risk factors, and health behaviors among adults&#xD;
      with elevated blood pressure/hypertension and short sleep duration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Half of U.S. adults have at least one cardio-metabolic disease (CMD), including hypertension&#xD;
      (HTN), heart disease, stroke, or diabetes. Even with advances in screening, education, and&#xD;
      medication management, controlling these chronic diseases remains challenging. Despite the&#xD;
      well-established negative effects of short sleep duration, surprisingly few studies have&#xD;
      tested the benefits of sleep extension and even fewer studies evaluate the science of sleep&#xD;
      extension interventions. Therefore, the goal of this study is to test the efficacy of a&#xD;
      behavioral sleep extension intervention on sleep duration, CMD risk factors, and health&#xD;
      behaviors among adults with elevated BP/HTN and short sleep duration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Investigators and outcomes assessors will not have access to the randomization table. Outcomes assessors will not be involved in the group assignments. Participants will be instructed to not tell outcomes assessors which group they are assigned to.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep duration</measure>
    <time_frame>8 weeks</time_frame>
    <description>Sleep duration will be measured using wrist actigraphy for 7 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 hour ambulatory blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Ambulatory blood pressure glycemic control, lipids).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour ambulatory blood pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Ambulatory blood pressure glycemic control, lipids).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep duration</measure>
    <time_frame>12 months</time_frame>
    <description>Sleep duration will be measured using wrist actigraphy for 7 days</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Diet</measure>
    <time_frame>8 weeks</time_frame>
    <description>24 hour diet recall</description>
  </other_outcome>
  <other_outcome>
    <measure>Diet</measure>
    <time_frame>12 months</time_frame>
    <description>24 hour diet recall</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Accelerometer measured activity over 7 days</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity</measure>
    <time_frame>12 months</time_frame>
    <description>Accelerometer measured activity over 7 days</description>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiometabolic marker</description>
  </other_outcome>
  <other_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Cardiometabolic marker</description>
  </other_outcome>
  <other_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiometabolic marker</description>
  </other_outcome>
  <other_outcome>
    <measure>IL-6</measure>
    <time_frame>8 weeks</time_frame>
    <description>Cardiometabolic marker</description>
  </other_outcome>
  <other_outcome>
    <measure>IL-6</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiometabolic marker</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Elevated Blood Pressure</condition>
  <condition>Habitual Sleep Duration of Less Than or Equal to 7 Hours</condition>
  <arm_group>
    <arm_group_label>Behavioral sleep extension group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the sleep extension group will receive a fitbit, weekly coaching calls and educational materials for 8 weeks. In months 3-6, they will receive educational materials and an email from the coach each month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Health education</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants in the health education group will receive 8 weekly health education emails and telephone calls to confirm their receipt and clarify any concepts from the materials. In months 3-6, they will receive monthly health education materials.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sleep extension intervention</intervention_name>
    <description>Participants will receive a fitbit and 8 weekly sleep-related educational materials via email and telephone coaching to review their sleep tracker data, set goals, trouble shoot any problems, and increase motivation.</description>
    <arm_group_label>Behavioral sleep extension group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Health education</intervention_name>
    <description>Participants will receive 8 weekly health education newsletters delivered via email.</description>
    <arm_group_label>Health education</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65&#xD;
&#xD;
          -  24h ABP readings indicating elevated blood pressure (BP) or hypertension (24h average&#xD;
             systolic (SBP) of 115-145 mmHg or diastolic (DBP) of 75-90 mmHg). Patients taking&#xD;
             antihypertensive medications will be permitted if stable dose for &gt;8 weeks&#xD;
&#xD;
          -  Time in bed &lt;8 hours and habitual sleep duration &lt;7 hours via actigraphy;&#xD;
&#xD;
          -  Smartphone user&#xD;
&#xD;
          -  Able to read/write in English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  High risk or presence of moderate to severe comorbid sleep disorders (i.e.,&#xD;
             obstructive sleep apnea AHI 15 or greater, restless legs syndrome, or insomnia) as&#xD;
             assessed by the questionnaires and overnight obstructive sleep apnea at the&#xD;
             baseline/screening&#xD;
&#xD;
          -  Resistant hypertension, defined as &gt;4 antihypertensive medications or taking&#xD;
             medications and standardized in lab BP &gt;130 mmHg SBP or 80 mmHg DBP at screening&#xD;
             History of cognitive or neurological disorders (e.g. dementia, Parkinson's, Multiple&#xD;
             Sclerosis)&#xD;
&#xD;
          -  BMI&gt;50 kg/m2 or arm circumference greater than extra large cuff&#xD;
&#xD;
          -  Presence of major psychiatric disorders (e.g. schizophrenia, bipolar disorder)&#xD;
&#xD;
          -  alcohol abuse on the Audit-C (score &gt;4 for men, &gt;3 for women)&#xD;
&#xD;
          -  drug use on the NIDA-Modified ASSIST (score &gt;3),90&#xD;
&#xD;
          -  moderate to severe depressive symptoms (PHQ-8 &gt;10)&#xD;
&#xD;
          -  Unstable or serious medical illness that would interfere with participation (cancer,&#xD;
             renal disease on dialysis)&#xD;
&#xD;
          -  Overnight work more than 1x per month&#xD;
&#xD;
          -  Use of hypnotic or stimulant medications&#xD;
&#xD;
          -  Situations that would significantly impact the ability to extend sleep, including&#xD;
             overnight caregiving responsibility for children under the age 1, elderly or disabled&#xD;
             adults &gt;1x per week&#xD;
&#xD;
          -  Inability to read or write in English&#xD;
&#xD;
          -  Pregnancy/desire to become pregnant during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kelly Baron, Ph.D.</last_name>
    <phone>8015857588</phone>
    <email>kelly.baron@utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sofia Vallejo</last_name>
    <phone>8015851123</phone>
    <email>sofia.vallejo@hsc.utah.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofia Vallejo, PhD</last_name>
      <email>sofia.vallejo@utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Baron, PhD</last_name>
      <phone>801-585-7588</phone>
      <email>kelly.baron@utah.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 13, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Kelly Glazer Baron</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be made available upon request to the investigators at the end of the study.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Within 1 year upon completion fo the study</ipd_time_frame>
    <ipd_access_criteria>Written request to the PI</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

